Adjunctive Olanzapine for SSRI-Resistant Combat-Related PTSD: A Double-Blind, Placebo-Controlled Study
Publication: American Journal of Psychiatry
Abstract
OBJECTIVE: Posttraumatic stress disorder (PTSD), particularly in combat veterans with chronic illness, is often refractory to standard pharmacological interventions. There is a need to test adjunctive treatments to boost response. METHOD: Subjects were 19 patients with PTSD who were minimally responsive to 12 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI) at maximum tolerated dose. Outcomes were compared among subjects whose treatment was augmented with 8 weeks of double-blind olanzapine or placebo administration. RESULTS: Olanzapine augmentation was associated with statistically significantly greater reduction than placebo in specific measures of posttraumatic stress, depressive, and sleep disorder symptoms. Clinician-rated global response rates did not, however, significantly differ between groups. CONCLUSIONS: This is most likely the first double-blind, placebo-controlled study of an adjunct to SSRIs for PTSD. Despite the small group size, the findings suggest a role for olanzapine or other atypical antipsychotics in treating SSRI-resistant PTSD. Sleep symptoms may especially benefit.
Posttraumatic stress disorder (PTSD) is a prevalent, often chronic, significantly disabling illness (1, 2). PTSD is responsive to treatment with selective serotonin reuptake inhibitors (SSRIs) (3, 4), but response rates rarely exceed 60%, and even fewer patients (20%–30%) experience improvement that could be characterized as remission. Consequently, a role exists for adjunctive treatments that might further improve outcomes.
Sleep disturbance is common among PTSD sufferers (5, 6), often proving particularly resistant to treatment. Several open-label reports (7–9) suggest that olanzapine, an atypical antipsychotic agent with prominent sedating properties, may be useful in treating PTSD, especially (but not solely) helping reduce sleep disturbances. However, olanzapine monotherapy did not prove superior to placebo in a double-blind pilot study of 15 patients with PTSD (10).
Combat exposure is known to result in a particularly virulent form of PTSD that tends to be chronic, disabling, and highly comorbid (11). One study (12) suggested that combat-related PTSD in veterans may be especially resistant to SSRI treatment, making this form of PTSD particularly apt for the testing of adjunctive therapies. To our knowledge, this is the first controlled trial to test the efficacy of an adjunctive pharmacological treatment for SSRI-resistant PTSD.
Method
Subjects were male patients from the VA San Diego Healthcare System with a clinically predominant diagnosis of DSM-IV PTSD (comorbid mood disorders were not exclusionary). The treating psychiatrist (M.B.S.) attempted to optimize their response to SSRI treatment by maximizing the dose, as tolerated. Patients whose PTSD symptoms were prospectively judged to be minimally responsive to 12 or more weeks (4 weeks or more at maximally tolerated doses) of treatment with an SSRI were eligible for the study. All subjects had chronic military-related PTSD; all but three were Vietnam veterans, with typical duration of illness in the range of 20–25 years. The presence of PTSD-related psychotic symptoms (13, 14) was not necessary for inclusion. All subjects provided informed written consent to participate in this study, which was approved by the University of California, San Diego, School of Medicine Human Research Protection Program.
Of the 21 patients enrolled in the study, two failed to return for their first medication assessment and were lost to follow-up. At the time of random assignment, of the remaining 19 patients (who are the subject of this report), five were taking fluoxetine (median dose: 40 mg/day), seven were taking paroxetine (median dose: 40 mg/day), and seven were taking sertraline (median dose: 200 mg/day). Subjects continued to take their maximally tolerated, stable dose of SSRI throughout the study and were randomly assigned to take either adjunctive olanzapine (10 mg) or placebo at bedtime for the first 2 weeks. This could then be increased to 20 mg at the next visit, if needed and tolerated. No other concurrent psychotropic medications were permitted.
Primary outcome measures were chosen to portray change in three symptom domains: posttraumatic stress (using the Clinician-Administered PTSD Scale for DSM-IV [15]), depressive (using the self-rated Center for Epidemiologic Studies Depression Scale [CES-D Scale] [16]), and sleep (using the self-report Pittsburgh Sleep Quality Index [17]) symptoms. Changes in these measures were compared across treatments, as were the numbers of responders in each period that were defined by the Clinical Global Impression (CGI) scale of change as “much improved” or “very much improved” relative to the start of treatment. Last observed scores were carried forward wherever possible for noncompleters; Pittsburgh Sleep Quality Inventory scores were available only for completers. Two-tailed tests were used, with p<0.05 deemed statistically significant.
Results
Mean scores at random assignment are shown in Table 1. Patients had severe PTSD and depressive symptoms and pronounced sleep problems. Olanzapine was associated with a significantly greater reduction than placebo in PTSD symptoms, as measured by total score on the Clinician-Administered PTSD Scale for DSM-IV: mean=–14.80 (SD=14.16) versus mean=–2.67 (SD=10.55), respectively (t=–2.21, df=17, p<0.05). It was also associated with a significantly greater reduction than placebo in sleep disturbance, as measured by the global score on the Pittsburgh Sleep Quality Index: mean=–3.29 (SD=3.15) versus mean=1.57 (SD=2.76) (t=–3.07, df=12, p=0.01). Change in Pittsburgh Sleep Quality Inventory score was moderately correlated with change in Clinician-Administered PTSD Scale for DSM-IV score (r=0.66, df=15, p=0.01), suggesting that enhanced sleep accounted for much of the reported improvement.
Olanzapine was also associated with a significantly greater reduction than placebo in depressive symptoms, as measured by the CES-D Scale: mean=–5.25 (SD=6.27) versus mean=4.88 (SD=9.66) (t=–2.49, df=14, p<0.03). The two treatments did not significantly differ in the percentage of subjects deemed responders on the CGI scale of change: three of 10 (30%) taking olanzapine versus one of nine (11%) taking placebo (p=0.58, Fisher’s exact test).
The mean dose of olanzapine was 15.00 mg/day (SD=5.25) compared to the mean dose of placebo, which was 20.00 mg/day (SD=0.00) (t=2.83, df=17, p<0.02). Weight gain was significantly greater with olanzapine than placebo: mean=13.2 lb (SD=5.9) versus mean=–3.0 lb (SD=6.5) (t=4.32, df=11, p=0.001). Early protocol terminations occurred for three patients taking olanzapine (two for somnolence; one for unspecified reasons) and for two patients taking placebo (both for lack of efficacy).
Discussion
We found the atypical antipsychotic olanzapine to be superior to placebo as an adjunct in the treatment of SSRI-resistant PTSD. Beneficial effects on sleep and depressive symptoms, in particular, were noted. Still, when global clinical improvement was considered, response rates to adjunctive olanzapine were fairly low (30%) and not statistically superior to placebo (11%). This suggests that although improvement in symptoms was attained with olanzapine, the overall magnitude of effects was modest for most patients (but clinically meaningful for some). Given the typical chronicity and severity of combat-related PTSD, even small gains (such as those seen in this study) must be cherished.
There is a subgroup of combat-related PTSD patients with psychotic symptoms (13, 14). These patients seem to have a more severe variant of PTSD and may benefit from the addition of antipsychotic agents to their treatment regimens. None of the patients in our study had psychotic symptoms, yet olanzapine was still helpful for some. This observation fits with emerging data in which olanzapine has been noted to successfully augment SSRI effects in two other conditions, even in the absence of psychotic symptoms: obsessive-compulsive disorder and major depressive disorder (18, 19).
Mean weight gain in subjects receiving olanzapine was approximately 13 lb. The benefits of using this antipsychotic agent in conjunction with an SSRI for treating PTSD must be balanced against the potential detrimental health effects associated with this magnitude of weight gain. Effects on glucose regulation should also be systematically evaluated (20).
We cannot rule out the possibility that more prolonged treatment with an SSRI would have resulted in additional improvement. Indeed, in one study in which sertraline treatment was continued up to 36 weeks (21), 20%–25% of the improvement in scores on the Clinician-Administered PTSD Scale for DSM-IV occurred between weeks 12 and 36. Practically, however, it is doubtful that most patients (or clinicians) would be willing to persist with a treatment that had negligible effects after 12 weeks in the hope that additional gains would accrue with prolonged treatment. There thus remains a clear need for interventions that can potentiate the effects of SSRIs for PTSD. Pharmacological (including olanzapine and other atypical antipsychotic agents) and psychological therapies should be systematically tested for this purpose under controlled conditions.
Footnote
Received Aug. 3, 2001; revisions received March 20 and April 25, 2002; accepted May 8, 2002. From the Anxiety and Traumatic Stress Disorders Programs, Psychiatry Service, VA San Diego Healthcare System, San Diego, Calif. Address reprint requests to Dr. Stein, Department of Psychiatry (0985), 9500 Gilman Dr., La Jolla, CA 92093-0985; [email protected] (e-mail). Supported by an investigator-initiated research grant from Eli Lilly. The authors thank Traci Bergthold, Rebecca Lenox, and the staff of the posttraumatic stress disorder clinical team at the VA San Diego Healthcare System outpatient clinic for help with patient care and recruitment. Dr. Stein is a paid consultant for Eli Lilly.
References
1.
Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB: Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048-1060
2.
Zatzick DF, Marmar CR, Weiss DS, Browner WS, Metzler TJ, Golding JM, Stewart A, Schlenger WE, Wells KB: Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am J Psychiatry 1997; 154:1690-1695
3.
Brady KT, Pearlstein T, Asnis GM, Baker DG, Rothbaum BO, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283:1837-1844
4.
Davidson JRT, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM: Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001; 58:485-492
5.
Mellman TA, Kulick-Bell R, Ashlock LE, Nolan B: Sleep events among veterans with combat-related posttraumatic stress disorder. Am J Psychiatry 1995; 152:110-115
6.
Engdahl B, Eberly R, Hurwitz T, Mahowald M, Blake J: Sleep in a community sample of elderly war veterans with and without posttraumatic stress disorder. Biol Psychiatry 2000; 47:520-525
7.
Labbate LA, Douglas S: Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD). Can J Psychiatry 2000; 45:667-668
8.
Prior T: Treatment of posttraumatic stress disorder with olanzapine (letter). Can J Psychiatry 2001; 46:182
9.
Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, Stone RC, Teten AL, Worchel J, Young KA: Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 2001; 16:331-337
10.
Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR: Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001; 16:197-203
11.
Prigerson HG, Maciejewski PK, Rosenheck RA: Combat trauma: trauma with highest risk of delayed onset and unresolved posttraumatic stress disorder symptoms, unemployment, and abuse among men. J Nerv Ment Dis 2001; 189:99-108
12.
van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55:517-522
13.
David D, Kutcher GS, Jackson EI, Mellman TA: Psychotic symptoms in combat-related posttraumatic stress disorder. J Clin Psychiatry 1999; 60:29-32
14.
Hamner MB, Frueh BC, Ulmer HG, Arana GW: Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol Psychiatry 1999; 45:846-852
15.
Weathers FW, Keane TM, Davidson JRT: Clinician-Administered PTSD Scale: a review of the first ten years of research. Depress Anxiety 2001; 13:132-156
16.
Radloff LS: The CES-D Scale: a self-report depression scale for research in the general population. J Applied Psychol Measurement 1977; 1:385-401
17.
Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28:193-213
18.
Bogetto F, Bellino S, Vaschetto P, Ziero S: Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000; 96:91-98
19.
Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131-134
20.
Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59:337-345
21.
Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, Patterson WM, Rausch J, Farfel GM: Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 2001; 62:325-331
Information & Authors
Information
Published In
History
Published online: 1 October 2002
Published in print: October 2002
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).